The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, in KRAS wild-type patients, BRAF mutations could have a predictive/prognostic value. Patients and Methods: We retrospectively analyzed objective tumor responses, time to progression, overall survival (OS), and the mutational status of KRAS and BRAF in 113 tumors from cetuximab- or panitumumab-treated metastatic CRC patients. The effect of the BRAF V600E mutation on cetuximab or panitumumab response was also assessed using cellular models of CRC. Results: KRAS mutations were present in 30% of the patients and were associated with resistance to cetuximab or panitumumab (P = .011). The BRAF V600E mutation was detected in 11 of 79 patients who had wild-type KRAS. None of the BRAF-mutated patients responded to treatment, whereas none of the responders carried BRAF mutations (P = .029). BRAF-mutated patients had significantly shorter progression-free survival (P = .011) and OS (P < .0001) than wild-type patients. In CRC cells, the introduction of BRAF V600E allele impaired the therapeutic effect of cetuximab or panitumumab. Treatment with the BRAF inhibitor sorafenib restored sensitivity to panitumumab or cetuximab of CRC cells carrying the V600E allele. Conclusion: BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment. Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the V600E oncogenic mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although therapies targeting EGFR have some efficacy in CRCs without KRAS mutations (1, 5–8)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [8]
In the citing paper
“However, the predictive impact of BRAF mutations is tempered by their low prevalence and is further biased by the prominent role of mutant BRAF as a negative prognostic biomarker [54]. Overall, the predictive power of this alteration remains immature and requires further prospective endorsement before clinical applicability [20, 33, 52, 55].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
In the citing paper
“Mutations of BRAF, which encodes the cytoplasmic serine/threonine kinase immediately downstream of RAS, are found in 4–13 % of advanced CRCs and are usually mutually exclusive with KRAS mutations [20, 52].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
In the citing paper
“preclinical studies have provided a proof of principle that the combined inhibition of EGFR and BRAF can be synergistic in BRAF-mutant CRCs”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
In the citing paper
“The BRAF V600E mutation has been described as a predictor of tumor aggressiveness in metastatic disease [33, 52, 53]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
In the citing paper
“the best responses of CRC cell xenografts to such combinations were only disease stabilizations or mild tumor regressions [52, 58-60].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
In the citing paper
“and also of low RRs to cetuximab and panitumumab [18, 20, 52, 53].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationSaltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S. R., Harris, J. E., Jessup, J. M., Kemeny, N. E., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,614
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,001
Stefano, A. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 45
Molecular Testing in Colorectal Cancer
Shi, C., & Washington, K. M. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpi83dinulujni · Cited by 43
Jivrajani, M. N., & Nivsarkar, M. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.06.004 · Cited by 43
Current Understanding of Urachal Adenocarcinoma and Management Strategy
Claps, M., Stellato, M., Zattarin, E., Mennitto, A., Sepe, P., Guadalupi, V., Mennitto, R., de Braud, F., Verzoni, E., & Procopio, G. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0878-z · Cited by 45
Connolly, K., Brungs, D., Szeto, E., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
“Several preclinical studies have demonstrated that transfection of the transcript containing the BRAF V600E mutation in wild-type cell systems confers resistance to both cetuximab and panitumumab.(33) A number of trials have shown a significant association between presence of BRAF mutations and resistance to anti-EGFR…”
BackgroundLin, H., Jiang, J., Liang, X., Zhou, X., & Huang, R. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.009 · Cited by 42
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population
Liou, J., Wu, M., Shun, C., Chiu, H., Chen, M., Chen, C.-C., Wang, H., Lin, J., & Liang, J. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1229-1 · Cited by 42
“Because KRAS is downstream effector of epidermal growth factor receptor (EGFR), recent studies showed that mutations in KRAS were predictive of treatment failure from EGFR-targeted therapy [3, 9, 10].”
ResultDasari, A. N., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2283 · Cited by 42
“Sorafenib is an oral multikinase inhibitor that targets both WT BRAF and oncogenic BRAF V600E and has in vitro activity in CRC cell lines with this mutation (34, 43).”
BackgroundJeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 43
“We found HER2 amplification (HER2/CEP17 ratio 2.0) in 4.9% of patients with mCRC whose tumors harbored wild-type RAS and BRAF.”
BackgroundInfluentialRankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 44
Self-citationColorectal Cancer: Pathogenesis and Targeted Therapy
Li, J., Pan, J., Wang, L., Ji, G., & Dang, Y. (2025) · MedComm · doi:10.1002/mco2.70127 · Cited by 48
“Human epidermal growth factor receptor (HER)2, a member of the HER family, is closely associated with the pathological features and progression of CRC. Targeting HER2 and its down-streamregulatorsisvitaltoovercomingdrugresistanceassociated with EGFR inhibitors [204].”
The role of tumor markers and biomarkers in colorectal cancer
Lech, G., Słotwiński, R., & Krasnodebski, I. W. (2013) · Neoplasma · doi:10.4149/neo_2014_003 · Cited by 41
Jiang, D., Wang, X., Wang, Y., Philips, D., Meng, W., Xiong, M., Zhao, J., Sun, L., He, D., & Li, K. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02576-y · Cited by 41
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma
Siraj, A. K., Bu, R., Prabhakaran, S., Bavi, P. P., Beg, S., Hazmi, M. A., Al-Rasheed, M. M., Alobaisi, K., Al‐Dayel, F., AlManea, H. M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-168 · Cited by 41
“8% in Netherlands and USA respectively [22-25,27-40].”
Chong, M. L., Loh, M. C. S., Thakkar, B. M., Pang, B., Iacopetta, B. J., & Soong, R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28444 · Cited by 40
Signal Transduction and Molecular Targets of Selected Flavonoids
Bode, A. M., & Dong, Z. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5251 · Cited by 41
“Activation of the EGFR primarily triggers the Ras/Raf/MEK/MAPK pathway, the PI3-K/PTEN/Akt/mTOR pathway, and the signal transducer and activator of transcription (STAT) signaling cascade (6, 37, 39, 63, 65) (Fig.”
BackgroundA growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 40
Aung, K. L., R. E. Board, Ellison, G., Donald, E. L., Ward, T. H., Clack, G., Ranson, M., Hughes, A. M., Newman, W. G., & Dive, C. (2010) · The HUGO Journal · doi:10.1007/s11568-011-9149-2 · Cited by 41
“Although increasing clinical relevance of BRAF and PIK3CA mutations in CRC is currently being recognized ( Di Nicolantonio et al. 2008; Sartore-Bianchi et al. 2009; Perrone et al. 2009), there is no study reporting significance of detecting BRAF and PIK3CA mutations in plasma or serum in CRC patients.”
Hou, W., Liu, J., Chen, P., Wang, H., Ye, B., & Qiang, F. (2014) · Oncology Letters · doi:10.3892/ol.2014.2253 · Cited by 40
“Thus, the mutational activation of NRAS and HRAS genes is an uncommon event in the pathogenesis of HCCs. BRAF mutations can abnormally activate downstream signaling pathways in HCC and act as indicator of cetuximab resistance in patients with colon cancer (34,35).”
KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Herreros‐Villanueva, M., Rodrigo, M., Claver, M., Múñiz, P., Lastra, E., Girón, C. G., & del Corral, M. J. C. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0232-x · Cited by 41
Lin, J. S., Webber, E. M., Senger, C. A., Holmes, R. S., & Whitlock, E. P. (2011) · PubMed · Cited by 40
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
Zhang, J., Yao, T.-W., Hashizume, R., Hariono, S., Barkovich, K. J., Fan, Q., Prados, M. D., James, C. D., Weiss, W. A., & Nicolaides, T. P. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2333-4 · Cited by 40
Khan, M., Loree, J. M., Advani, S., Ning, J., Li, W., Pereira, A. A. L., Lam, M. S., Raghav, K. P. S., Morris, V. K., Broaddus, R. R., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.005 · Cited by 40
Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine
Chauvin, A., & Boisvert, F. (2018) · Proteomes · doi:10.3390/proteomes6040049 · Cited by 41
Fan, X., Wan, X., Fu, X., Wu, P., Chen, D., Wang, P.-N., Li, J., Wang, D., Chen, Z., Huang, Y. J., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2320-3 · Cited by 40
Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38
Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer
Kang, M. S., Shen, X., Kim, S., Araújo-Pérez, F., Galanko, J. A., Martin, C. F., Sandler, R. S., & Keku, T. O. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130366 · Cited by 40
“Similarly, tumors with BRAF mutations have been associated with worse prognosis and a decreased response to anti-EGFR antibody therapies for advanced CRC [8,14,25,30].”
BRAF Mutation Testing in Colorectal Cancer
Sharma, S. G., & Gulley, M. L. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0232-rs.1 · Cited by 38
Kelley, R. K., Bebber, S. L. V., Phillips, K. A., & Venook, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0004 · Cited by 40
Manzari, M. T., Rosalia, E. K., Chen, T. F., Wittrup, K. D., & Spangler, J. B. (2012) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 39
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 40
Johnson, B., Jin, Z., Truty, M. J., Smoot, R. L., Nagorney, D. M., Kendrick, M. L., Kipp, B. R., & Grothey, A. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0230 · Cited by 41
Yao, J., Zang, W., Ge, Y., Weygant, N., Yu, P., Li, L., Rao, G., Jiang, Z., Yan, R., He, L., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/4248971 · Cited by 40
“As BRAFmutation cases are very rare inCRCpatients [16, 17] and only two patients in this study hadBRAFmutated,”
BackgroundPeeters, M., Price, T. J., Boedigheimer, M. J., Kim, T. W., Ruff, P., Gibbs, P., Thomas, A., Demonty, G., Hool, K., & Ang, A. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2072 · Cited by 39
Gutierrez, M. E., Price, K. S., Lanman, R. B., Nagy, R. J., Shah, I., Mathura, S., Mulcahy, M., Norden, A. D., & Goldberg, S. L. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00274 · Cited by 39
“BRAF mutations, specifically V600E, predict lack of response to cetuximab and panitumumab in another 9%.(5,6) ERBB2 (HER2) amplification, present in approximately 2% of mCRC, is also a negative predictor of anti-EGFR MAb response, increasing the percentage of patients with mCRC in whom these ineffective agents could b…”
BackgroundEGFR targeting drugs in the treatment of head and neck squamous cell carcinoma
Sundvall, M., Karrila, A., Nordberg, J., Grenman, R. A., & Elenius, K. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728211003716442 · Cited by 39
“For example, many clinical studies have shown that activating mutations of K-Ras or B-Raf, components of MAPK cascade downstream of EGFR (Figure 1), associate with resistance to EGFR targeting mAbs in colorectal cancer patients [100,101].”
Tie, J., & Desai, J. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0330-0 · Cited by 38
“[50] in their retrospective analysis of 113 colorectal tumors from patients who received anti-EGFR mAbs in second or subsequent lines of treatment showed that 0/11 (0 %) tumors with BRAFmutation responded to anti-EGFR treatment compared to 22/68 (32 %) of BRAF wild-type/KRAS wild-type tumors.”
ResultSalto‐Tellez, M., Tsao, M., Shih, J., Thongprasert, S., Lü, S., Chang, G., Au, J. S. K., Chou, T., Lee, J. S., Shi, Y.-K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227816a · Cited by 38
Loupakis, F., Cremolini, C., Salvatore, L., Schirripa, M., Lonardi, S., Vaccaro, V., Cuppone, F., Giannarelli, D., Zagonel, V., Cognetti, F., et al. (2011) · Cancer · doi:10.1002/cncr.26460 · Cited by 38
Proteins are potent biomarkers to detect colon cancer progression
Kuppusamy, P., Govindan, N., Yusoff, M. M., & Ichwan, S. J. A. (2014) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2014.09.017 · Cited by 38
Targeted Therapies: The Rare Cancer Paradigm
Pierotti, M. A., Negri, T., Tamborini, E., Perrone, F., Pricl, S., & Pilotti, S. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.10.003 · Cited by 38
“In particular, mutations of BRAF, the main downstream effector of KRAS, were described as mutually exclusive to KRAS mutations and associated with resistance to EGFR-targeted MoAbs therapies in about 10% of KRAS wild-type CRC patients (Di Nicolantonio et al., 2008).”
BackgroundLi, W., Qiu, T., Guo, L., & Ying, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.014 · Cited by 38
Kim, N., Cho, D., Kim, H., Kim, S., Cha, Y., Greulich, H. E., Bass, A. J., Cho, H., & Cho, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32499 · Cited by 40
Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges
Kolenčík, D., Shishido, S. N., Pitule, P., Mason, J., Hicks, J. B., & Kuhn, P. (2020) · Cancers · doi:10.3390/cancers12061376 · Cited by 34
“Subsequently, BRAF mutation can be used as a prognostic factor and in clinical decision-making regarding targeted therapy [41,42].”
BackgroundAgarwal, V., Lind, M., & Cawkwell, L. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.11.004 · Cited by 38
Bisht, S., Ahmad, F., Sawaimoon, S. K., Bhatia, S., & Das, B. R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0124-3 · Cited by 40
“Furthermore, in agreement with the previous findings, none of the KRAS mutation cases harbored concurrent BRAF mutations, indicating that these mutations were mutually exclusive which is in line with the previous findings [13, 18].”
BackgroundResultInfluentialIzar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Kriegsmann, M., Arens, N., Endris, V., Weichert, W., & Kriegsmann, J. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0364-3 · Cited by 39
“As with KRAS mutations (especially codon 12), BRAF mutations have also been linked to a worse patient prognosis in CRC [8, 20].”
BackgroundSoeda, H., Shimodaira, H., Watanabe, M., Suzuki, T., Gamoh, M., Mori, T., Komine, K., Iwama, N., Kato, S., & Ishioka, C. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0422-8 · Cited by 37
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
Savonarola, A., Palmirotta, R., Guadagni, F., & Silvestris, F. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.28 · Cited by 36
Grimminger, P., Shi, M., Barrett, C. J., Lebwohl, D., Danenberg, K. D., Brabender, J., Vigen, C. L. P., Danenberg, P. V., Winder, T., & Lenz, H. J. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.29 · Cited by 37
Recent approaches to identifying biomarkers for high-risk stage II colon cancer
Akiyoshi, T., Kobunai, T., & Watanabe, T. (2012) · Surgery Today · doi:10.1007/s00595-012-0324-4 · Cited by 36
“In patients with metastatic colorectal cancer, BRAF mutations have been shown to be predictive of a lack of response to anti-EGFR-targeted agents [41], and to be associated with poor survival [42].”
BackgroundConcordant analysis of KRAS status in primary colon carcinoma and matched metastasis.
Mariani, P., Lae, M. E., Degeorges, A., Cacheux, W., Lappartient, E., Margogne, A., Pierga, J., Girre, V., Mignot, L., Falcou, M. C., et al. (2010) · PubMed · Cited by 37
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pinto, P., Rocha, P., Veiga, I., Guedes, J. G., Pinheiro, M., Peixoto, A., Pinto, C., Fragoso, M., Sanches, E., Araújo, A., et al. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.003 · Cited by 37
Wangefjord, S., Sundström, M., Zendehrokh, N., Lindquist, K. E., Nodin, B., Jirström, K., & Eberhard, J. (2013) · Biology of Sex Differences · doi:10.1186/2042-6410-4-17 · Cited by 36
“BRAF mutation has also been linked to an impaired prognosis in CRC [9,15,16] and unresponsiveness to anti-EGFR drugs [17-19].”
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy
Murcia, Ó., Juárez, M., Hernández‐Illán, E., Egoavil, C. M., Giner-Calabuig, M., Soler, M. R., & Jover, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i13.3516 · Cited by 39
Bağcı, B., Sari, M., Karadayı, K., Turan, M., Özdemir, Ö., & Bağcı, G. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160624 · Cited by 37
“cally have a prognostic significance in colorectal cancer [16,52,56].”
BackgroundBRAF-Directed Therapy in Metastatic Colorectal Cancer
Korphaisarn, K., & Kopetz, S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000189 · Cited by 38
Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer
von Bubnoff, N. C. C. (2017) · Oncology Research and Treatment · doi:10.1159/000478864 · Cited by 38
BRAFmutation testing in clinical practice
Ziai, J. M., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.1 · Cited by 37
Hotz, B., Keilholz, U., Fusi, A., Buhr, H. J., & Hotz, H. G. (2011) · Gastric Cancer · doi:10.1007/s10120-011-0102-9 · Cited by 37
“Together with K-ras, BRAF, a downstream gene of the RAS pathway, is also known to be somatically mutated in a number of human cancers, and BRAF mutations have been associated with resistance to EGFR-targeted antibody therapies [17].”
BackgroundBekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad200 · Cited by 36
Martinelli, E., Cremolini, C., Mazard, T., Vidal, J., Virchow, I., Tougeron, D., Cuyle, P., Chibaudel, B., Kim, S. C. H., Ghanem, I., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100603 · Cited by 38
Somatic alterations as the basis for resistance to targeted therapies
Blair, B. G., Bardelli, A., & Park, B. H. (2013) · The Journal of Pathology · doi:10.1002/path.4278 · Cited by 36
“Specifically, the V600E activating mutation is strongly associated to poor response to EGFR antibody therapy [124].”
Self-citationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Vincenzi, B., Cremolini, C., Bianchi, A. S., Russo, A. D., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5231 · Cited by 36
“Among these, downstream mutations such as in B-Raf and PIK3CA genes have been investigated through several sequencing methods [9-11].”
BackgroundSelf-citationCetuximab in metastatic colorectal cancer
Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.25 · Cited by 36
Cui, D., Cao, D., Yang, Y., Qiu, M., Huang, Y., & Cheng, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2974-8 · Cited by 36
Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
Gonzaga, I., Soares-Lima, S., de Santos, P. T. S., Blanco, T., de Reis, B. S. B., Quintella, D., de Oliveira, I. M., de Faria, P. D., Kruel, C. D., Andreollo, N., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-569 · Cited by 37
“The most frequent mutations observed in colorectal cancer patients are found at codons 12 and 13 of KRAS, in approximately 35% of the patients, and the V600E mutation of BRAF, found in about 15% of the cases [19,34].”
BackgroundShankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36
Huang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33
Höchster, H. S., Uboha, N. V., Messersmith, W. A., Gold, P. J., O’Neil, B. H., Cohen, D. J., Denlinger, C. S., Cohen, S., Leichman, C. G., & Leichman, L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2609-3 · Cited by 36
“The presence of these mutations results in resistance to the EGFR-targeted therapy [5, 7, 8].”
BackgroundRAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., Glimelius, B. L. G., Roselló, S., Wotherspoon, A. C., Brown, G. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.002 · Cited by 35
“Moreover, data were also emerging suggesting a possibly similar role for the mutations of the BRAF gene [15].”
BackgroundKu, G. Y., Haaland, B. A., & Lopes, G. D. L., Jr. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1898-7 · Cited by 35
Lewandowska, M. A., Jóźwicki, W., & Żurawski, B. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0025-8 · Cited by 35
van Eijk, R., van Puijenbroek, M., Chhatta, A. R., Gupta, N., Vossen, R. H. A. M., Lips, E. H., Cleton-Jansen, A., Morreau, H. M., & van Wezel, T. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090028 · Cited by 35
“In other cancers, KRAS mutations are less frequent or only present in specific subsets, such as subsets of bladder, endometrial, thyroid, and liver cancers (2-5).”
BackgroundBidshahri, R., Attali, D., Fakhfakh, K., McNeil, K., Karsan, A., Won, J., Wolber, R. A., Bryan, J., Hughesman, C. B., & Haynes, C. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.09.003 · Cited by 35
“asp, last accessed August 25, 2015) also recommend BRAF mutational testing of MLH1-deficientCRCpatients, because the antitumor activity of anti-EGFR antibodies (cetuximab, panitumumab) may be suppressed or lost in BRAF-positive patients.(32) Moreover, the BRAF mutation correlates well with adverse pathologic features…”
BackgroundChang, Y., Chang, M., Huang, K., Tung, C., Hsu, C., & Wong, J. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12505 · Cited by 35
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Saridaki, Z. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i10.1177 · Cited by 34
Integration of panitumumab into the treatment of colorectal cancer
Grávalos, C., Cassinello, J., Alfonso, P. G., & Jimeno, A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.06.005 · Cited by 35
Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
Sakai, K., Tsurutani, J., Yamanaka, T., Yoneshige, A., Ito, A., Togashi, Y., Velasco, M. A. D., Terashima, M., Fujita, Y., Tomida, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121891 · Cited by 36
“KRAS and BRAFmutations are considered to be mutually exclusive [17].”
BackgroundLung cancer biomarkers, targeted therapies and clinical assays.
Patel, J. N., Ersek, J. L., & Kim, E. S. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.02 · Cited by 34
BRAF — A new player in hematological neoplasms
Machnicki, M. M., & Stokłosa, T. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.01.001 · Cited by 34
Carbonell, P., Turpín, M. C., Torres‐Moreno, D., Molina-Martínez, I., García‐Solano, J., Pérez‐Guillermo, M., & Conesa‐Zamora, P. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.03.009 · Cited by 34
Berg, M., Nordgård, O., Kørner, H., Oltedal, S., Smaaland, R., Søreide, J. A., & Søreide, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122391 · Cited by 34
“A double activation of the MAPK pathway has been suggested to lead to differentiation and cell senescence, rather than growth promotion as is the result of a single mutation [51].”
BackgroundThe role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Moorcraft, S. Y., Smyth, E. C., & Cunningham, D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13491797 · Cited by 35
Gajate, P., Sastre, J., Bando, I., Alonso, T., Cillero, L., Sanz‐Ortega, J., Caldés, T., & Díaz‐Rubio, E. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.02.003 · Cited by 37
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond
Malapelle, U., Carlomagno, C., Luca, C. D., Bellevicine, C., & Troncone, G. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201835 · Cited by 34
“Although the presence of BRAF in its wild-type form is required for response to treatment, 124 BRAF mutations de fi ne a genetically distinct subset of CRCs characterised by an extremely poor prognosis.”
BackgroundOuchi, K., Takahashi, S. I., Yamada, Y., Tsuji, S., Tatsuno, K., Takahashi, H., Takahashi, N., Takahashi, M., Shimodaira, H., Aburatani, H., et al. (2015) · Cancer Science · doi:10.1111/cas.12827 · Cited by 35
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
Statin Treatment as a Targeted Therapy for APC-Mutated Colorectal Cancer
Shailes, H., Tse, W. Y., Freitas, M. O., Silver, A., & Martin, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880552 · Cited by 34
“However, cetuximab is ineffective in the presence of K-Ras and B-RAF mutations that are very common in CRC, therefore indicating that targeting alternative driver mutations may be more effective (17, 18).”
BackgroundThe long road to colorectal cancer therapy: Searching for the right signals
Hollande, F., Pannequin, J., & BRESSION, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.01.002 · Cited by 34
Al-Marrawi, M. Y., Saroya, B. S., Brennan, M., Yang, Z., Dykes, T. M., & El‐Deiry, W. S. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25191 · Cited by 34
“com Cancer Biology & Therapy 705 less response to panitumumab or cetuximab as compared with BRAF wild-type tumors in metastatic colorectal cancer.(5-7) Despite the treatment with FOLFIRI plus cetuximab, her CEA levels progressively rose and a repeat PET/CT after 3 cycles revealed increased size of the aortocaval nodes.”
BackgroundPredictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach
Kulendran, M., Stebbing, J. F., Marks, C. G., & Rockall, T. (2011) · Cancers · doi:10.3390/cancers3021622 · Cited by 35
“CIMP-H tumors found to be MSI positive and haboring the BRAF mutation have a good prognosis [59].”
BackgroundInfluentialHägerstrand, D., Lindh, M. B., Peña, C., Garcı́a-Echeverrı́a, C., Nistér, M., Hofmann, F., & Östman, A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq029 · Cited by 34
“Finally, BRAF mutations also reduce sensitivity to EGFR-targeting antibodies.(37) So far, the effects of the status of downstream signaling pathways on sensitivity to IGF-1 receptor inhibitors have not been reported.”
BackgroundPatient-derived organoid analysis of drug resistance in precision medicine: is there a value?
Abugomaa, A., & Elbadawy, M. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1715794 · Cited by 35
Li, Y., Wang, B., Yang, W., Ma, F., Zou, J., Li, K., Tan, S., Feng, J., Wang, Y., Qin, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44911-1 · Cited by 32
Ibrahem, S., Seth, R., O’Sullivan, B., Fadhil, W., Tanière, P., & Ilyas, M. (2010) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2010.00733.x · Cited by 33
“Furthermore, even tumours with wild type KRAS may not respond if they harbour a BRAF mutation as this lies downstream of KRAS (Di Nicolantonio et al. 2008).”
BackgroundWierling, C., Kühn, A., Hache, H., Daskalaki, A., Maschke-Dutz, E., Peycheva, S., Li, J., Herwig, R., & Lehrach, H. R. (2012) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2012.01.005 · Cited by 33
Metadata
- Authors
- Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., & Bardelli, A.
- Affiliations
- From the Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo; The Falck Division of Medical Oncology, Ospedale Niguarda Ca’ Granda; Italian Foundation for Cancer Research–Institute of Molecular Oncology, Milan, Italy; Laboratory of Molecular Diagnostic, Istituto Cantonale di Patologia, Locarno; and Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Venue
- Journal of Clinical Oncology
- Published
- 2008-12-10
- Volume
- 26
- Issue
- 35
- Pages
- 5705-5712
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131413118
- Cited by
- 1,591
- References
- 38
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 25 · 2023: 32 · 2022: 35 · 2021: 48 · 2020: 71 · 2019: 54 · 2018: 57 · 2017: 67 · 2016: 126 · 2015: 108 · 2014: 147 · 2013: 146 · 2012: 148
- FWCI
- 87.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Oncosuisse
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- BRAF wild-type, BRAF V600E mutation, KRAS mutation, cetuximab, panitumumab, metastatic colorectal cancer, EGFR inhibitors, treatment resistance, sorafenib, predictive biomarkers, progression-free survival, overall survival
- MeSH terms
- Cetuximab, Sorafenib, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Benzenesulfonates, Cell Survival, Dose-Response Relationship, Drug, Female, Humans, Italy, Male, Middle Aged, Mutation, Neoplasm Metastasis, Niacinamide, Phenylurea Compounds, Proto-Oncogene Proteins, Pyridines, Retrospective Studies, Switzerland, Time Factors, Biomarkers, Tumor, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, Patient Selection, ras Proteins, Drug Resistance, Neoplasm, HT29 Cells, Gene Expression Profiling, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
